AG00I8P5

477600-75-2 | 3-[(3S,4S)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile

Chemical structure of 3-[(3S,4S)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile, CAS 477600-75-2
AG00I8P5
sdsSDS
sdsCOA
TIP This product is typically in stock.Please contact us for quotation.
Request For Quotation

CAS Number 477600-75-2
Catalog Number AG00I8P5(AGN-PC-02MPBV)
Chemical Name 3-[(3S,4S)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
IUPAC Name 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
InChI InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1
InChI Key UJLAWZDWDVHWOW-YPMHNXCESA-N
MDL Number MFCD11035919
Molecular Formula C16H20N6O
Molecular Weight 312.3696
SMILES C[C@H]1[C@H](CN(CC1)C(CC#N)=O)N(C=1C2=C(N=CN1)NC=C2)C
UNII 87LA6FU830
Synonyms
CP 690,550, CP 690550, CP-690,550, CP-690550, CP690550, tasocitinib, tofacitinib, tofacitinib citrate, Xeljanz, Tofacitinib, Tasocitinib, 477600-75-2, 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile, CP-690550, CP 690550, racemic-tofacitinib, 1259404-17-5, tofacitinibum, Tofacitinib (CP-690550,Tasocitinib), CP-690,550, UNII-87LA6FU830, 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile, 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile, CHEMBL221959, CHEBI:71200, 87LA6FU830, MFCD11035919, 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-, (3R,4R)-, 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile, 3-[(3R,4R)-4-methyl-3-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile, 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile, Tofacitinib [USAN:INN], C16H20N6O, 3eyg, 3fup, 3lxk, 4oti, AK-68808, MI1, Tofacitinib (USAN), PubChem16767, tofacitinib-cp-690550, CP-690550(Tasocitinib), SCHEMBL322753, GTPL5677, QCR-53, CTK3J8304, HSDB 8311, DTXSID90197271, EX-A205, UJLAWZDWDVHWOW-YPMHNXCESA-N, BCPP000274, AOB87470, KS-000001IG, KS-000006RA, ZINC3818808, ABP000824, ANW-51607, BDBM50193995, CP-690, s2789, AKOS005145814, AKOS005258733, AC-8193, BCP9000550, CA10005, CC-1770, CS-0050, DB08895, GS-6106, PB20522, RL03781, SB20004, SB20005, NCGC00229511-02, NCGC00229511-04, NCGC00244463-01, Tofacitinib (CP-690550, Tasocitinib), AJ-45724, AK172116, BC660087, CP690550(Tasocitinib)/CP-690550, HY-40354, SC-21829, TZ000640, AB0007916, TR-009964, TX-016530, FT-0083764, W6440, D09970, Q-9324, AB01565786_02, 600M752, J-524314, BRD-K31283835-001-01-9, BRD-K31283835-048-04-4, 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyr, 3-((3R,4R)-4-Methyl(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yi)Amino)Piperidin-1-Yl-3-Oxopropaneni, (3R,4R)-3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile, (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine propanenitrile, 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitr, 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidyl]-3-oxo-propanenitrile, 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]piperidin-1-yl}-3-oxo-propionitrile, 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile, 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo(2,3-d)pyrimidin-4-yl-, (3R,4R)-, dichloro[(r)-(+)-2,2-bis(diphenylphosphino)-1,1-binaphthyl][(1r,2r)-(+)-1,2-diphenylethylenediamine], dichloro[(r)-(+)-2,2-bis(diphenylphosphino)-1,1-binaphthyl][(1r,2r)-(+)-1,2-diphenylethylenediamine]ruthenium(ii), Xeljanz, Tofacitinib citrate, racemic-Tasocitinib, Xeljanz (TN), Tofacitinib [USAN], D0EG1I, D0O2KL, cc-396, MFCD11616529, Tofacitinib, 99% - 10MG 10mg, ACN-031566, CID9926791, CS-O-10853, CID 9926791, CP690550, A4138, CP 690,550, C479163, 212143-23-2, (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile, 3-(4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile, 916591-01-0, 937669-80-2,

Related Research Chemicals

CERTIFICATE OF ANALYSIS
Chemical Name: Batch Number:
Chemical Structure: CAS Registry No:
Product ID:
Manufacture Date:
Storage Temperature:
Formula:
Molecular Weight:
Quantity:
Analysis Data:
Test: Result:
Conclusion: The above product meets the specifications of Angene.
Analyst:Chase
Date:
Reviewed by:Jessie
Date:
Angene International Limited